4653-08-1

Basic information

• Product Name: 4-OXO-4-(2-THIENYL)BUTYRIC ACID
• Synonyms: 3-(2-THENOYL)PROPIONIC ACID;4-OXO-4-THIEN-2-YLBUTANOIC ACID;4-OXO-4-(THIOPHEN-2-YL)BUTANOIC ACID;4-OXO-4-THIOPHEN-2-YL-BUTYRIC ACID;4-OXO-4-(2-THIENYL)BUTANOIC ACID;4-OXO-4-(2-THIENYL)BUTYRIC ACID;3-(ALPHA-THENOYL)PROPIONIC ACID;4-OXO-4-(2-THIENYL)BUTYRIC ACID 95%
• CAS NO: 4653-08-1
• Molecular Formula: C₈H₈O₃S
• Molecular Weight: 184.21
• EINECS: 225-089-5
• Product Categories: Heterocyclic Compounds;Building Blocks;Heterocyclic Building Blocks;Thiophenes
• Mol File: 4653-08-1.mol

Chemical Properties

• Melting Point: 118-121 °C(lit.)
• Boiling Point: 400.5°Cat760mmHg
• Flash Point: 196°C
• Appearance: /
• Density: 1.334g/cm³
• Vapor Pressure: 3.93E-07mmHg at 25°C
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• BRN: 133870
• CAS DataBase Reference: 4-OXO-4-(2-THIENYL)BUTYRIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-OXO-4-(2-THIENYL)BUTYRIC ACID(4653-08-1)
• EPA Substance Registry System: 4-OXO-4-(2-THIENYL)BUTYRIC ACID(4653-08-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• TSCA: Yes
• HazardClass: IRRITANT
• Hazardous Substances Data: 4653-08-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-OXO-4-(2-THIENYL)BUTYRIC ACID is used as an intermediate in the synthesis of pharmaceutical compounds for its unique structural features and reactivity. Its presence in the molecular structure can contribute to the development of new drugs with potential therapeutic benefits.
Used in Chemical Synthesis:
In the field of organic chemistry, 4-OXO-4-(2-THIENYL)BUTYRIC ACID is used as a building block for the synthesis of various organic compounds. Its oxo and 2-thienyl groups at the 4-position provide a versatile platform for further chemical reactions and modifications, leading to the creation of novel molecules with specific properties.
Used in Research and Development:
4-OXO-4-(2-THIENYL)BUTYRIC ACID is utilized in research and development settings to explore its potential applications and properties. Scientists and researchers use this compound to investigate its reactivity, stability, and interactions with other molecules, which can lead to the discovery of new applications and insights into its chemical behavior.
Used in Material Science:
In material science, 4-OXO-4-(2-THIENYL)BUTYRIC ACID can be employed as a component in the development of new materials with specific properties. Its unique structure and chemical properties can contribute to the creation of materials with tailored characteristics, such as improved stability, reactivity, or other desirable attributes.

InChI:InChI=1/C8H8O3S/c9-6(3-4-8(10)11)7-2-1-5-12-7/h1-2,5H,3-4H2,(H,10,11)/p-1

Upstream product

• 188290-36-0 thiophene 
• 108-30-5 succinic acid anhydride 
• 14794-31-1 ethyl 3-(chloroformyl)propionate 
• 543-20-4 succinoyl dichloride 
• 17960-38-2 4-oxo-4-(thiophen-2-yl)butanenitrile 
• 110-15-6 succinic acid 
• 59086-25-8 ethyl 4-oxo-4-(thiophen-2-yl)butanoate 
• 75288-42-5 4-hydroxy-1-(thiophen-2-yl)-butan-1-one 
• 289652-61-5 4-(thiophen-2-yl)but-3-yn-1-ol 
• 170115-17-0 tert-butyl 3-oxo-3-(thien-2-yl)propanoate 
• 1027034-67-8 2-(Thiophene-2-carbonyl)-succinic acid 1-tert-butyl ester 4-ethyl ester 
• 5424-47-5 3-(dimethylamino)-1-(thiophen-2-yl)propan-1-one hydrochloride 

Downstream Products

• 104-50-7 gamma-octalactone 
• 4653-11-6 2-thiophenebutyric acid 
• 53515-21-2 3-bromo-4-oxo-4-thiophen-2-yl-butyric acid 
• 54558-00-8 2-(4-chloro-phenyl)-6-thiophen-2-yl-4,5-dihydro-2H-pyridazin-3-one 
• 52240-00-3 6-(thien-2-yl)-2,3,4,5-tetrahydropyridazin-3-one 
• 135509-64-7 3-(4-Benzyl-piperazin-1-ylmethyl)-4-oxo-4-thiophen-2-yl-butyric acid 
• 59086-25-8 ethyl 4-oxo-4-(thiophen-2-yl)butanoate 
• 492-97-7 2,2'-Bithiophene 
• 4316-44-3 4-oxooctanoic acid 
• 58931-00-3 4,13-dioxo-hexadecanedioic acid 
• 101448-19-5 1,8-bis-(5-oxo-tetrahydro-[2]furyl)-octane 
• 371149-29-0 N,N-diisopropyl-4-(2-thienyl)-4-oxobutanamide 
• 371149-32-5 4-methoxyphenyl-4-(2'-thienyl)-4-oxobutanamide 
• 371149-33-6 2'',4''-dimethoxyphenyl-4-(2'-thienyl)-4-oxobutanamide 

Relevant articles and documents

NEW SYNTHESIS OF 1-TRIACONTANOL

Succinic anhydride and behenic acid have been used to attach C4 and C22 carbon chains on to 2 and 5 positions of thiophene through two alternate acylation sequences.Raney nickel desulphurization to the 2,5-disubstituted thiophene yielded triacontanoic acid esters which on LAH reduction gave 1-triacontanol.

NEAR-INFRARED ABSORBING DYE, OPTICAL FILTER, AND IMAGING DEVICE

A near-infrared absorbing dye includes a compound represented by formula (A). Each of R11 to R14 is independently a hydrogen atom, a halogen atom, a hydroxyl group, or an alkyl, aryl or alaryl group. Each of pairs R11 and R12, R12 and R13, and R13 and R14 may combine with one another to form a monocyclic ring or a polycyclic ring in which from 2 to 4 rings are fused. Each of R15 and R16 is independently an alkyl or alaryl group. R15 and R16 may combine with one another to form a cyclohetero ring having from 5 to 10 members together with the nitrogen atom.

Visible Light-Driven, Copper-Catalyzed Aerobic Oxidative Cleavage of Cycloalkanones

A visible light-driven, copper-catalyzed aerobic oxidative cleavage of cycloalkanones has been presented. A variety of cycloalkanones with varying ring sizes and various α-substituents reacted well to give the distal keto acids or dicarboxylic acids with moderate to good yields.

Synthesis, anti-convulsant activity and molecular docking study of novel thiazole pyridazinone hybrid analogues

Pyridazinone analogues have been known to be potential candidates for anticonvulsant agents. We have identified several pyridazinone-based anticonvulsant agents. As a continuation to our previous research, a series of hybrid pyridazinone-thiazole connected through amide linkage were designed and synthesized. Among these, compound SP-5F demonstrated significant anticonvulsant activity with median effective dose of 24.38 mg/kg (MES) and 88.23 mg/kg (scPTz). Results of GABA estimation showed a marked increase in the GABA level when compared with control. Molecular docking studies at the active site of GABA receptor, further confirmed the GABA modulatory effects of SP-5F.

Novel synthetic method for duloxetine intermediate

The invention provides a novel synthetic method for a duloxetine intermediate (S)-N-methyl-3-hydroxy-3-(2-thienyl)-1-propylamine (a compound 1 as described in the specification). According to the method, thiophene and succinic anhydride are used as raw materials and undergo Friedel-Crafts acylation, esterification, aminolysis, asymmetric hydrogenation, and oxidative degradation so as to obtain theduloxetine intermediate (the compound 1).

AGONISTS OF THE CHEMOKINE RECEPTOR CXCR3

The present invention relates to agonists of the chemokine receptor CXCR3, methods of their synthesis and uses thereof.

Design, Synthesis, and Pharmacological Screening of Pyridazinone Hybrids as Anticonvulsant Agents

A series of new hybrid benzimidazole containing pyridazinones derivatives were designed and synthesized in accordance with the pharmacophoric requirements essential for the anticonvulsant activity. The synthesized compounds were evaluated for anticonvulsant activity on mice by the gold standard maximal electroshock (MES) and subcutaneous pentylenetetrazole (scPTZ)-induced seizure models. Among the compounds tested, SS-4F showed significant anticonvulsant activity in both the screens with ED50 values of 25.10 and 85.33 mg/kg in the MES and scPTZ screens, respectively. Compound SS-4F emerged as safer and effective anticonvulsant due to its several-fold higher protective indices. Further, the gamma-aminobutyric acid (GABA) estimation result showed a marked increase in the GABA level (1.7-fold) as compared to the control, which was further confirmed by good binding properties with the GABAA receptor.

Discovery and Characterization of Biased Allosteric Agonists of the Chemokine Receptor CXCR3

In this work we report a design, synthesis, and detailed functional characterization of unique strongly biased allosteric agonists of CXCR3 that contain tetrahydroisoquinoline carboxamide cores. Compound 11 (FAUC1036) is the first strongly biased allosteric agonist of CXCR3 that selectively induces weak chemotaxis and leads to receptor internalization and the β-arrestin 2 recruitment with potency comparable to that of the chemokine CXCL11 without any activation of G proteins. A subtle structural change (addition of a methoxy group, 14 (FAUC1104)) led to a contrasting biased allosteric partial agonist that activated solely G proteins, induced chemotaxis, but failed to induce receptor internalization or β-arrestin 2 recruitment. Concomitant structure-activity relationship studies indicated very steep structure-activity relationships, which steer the ligand bias between the β-arrestin 2 and G protein pathway. Overall, the information presented provides a powerful platform for further development and rational design of strongly biased allosteric agonists of CXCR3.

NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTAGONISTS

Novel tricyclic compounds of Formula (I) and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing osteoporosis and similar conditions. The compounds are effective as calcium sensing receptor antagonists. Pharmaceutical compositions and methods of treatment are also included.

NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OSTEOPOROSIS

Novel tricyclic compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing osteoporosis and similar conditions. The compounds are effective as calcium sensing receptor antagonists. Pharmaceutical compositions and methods of treatment are also included.